DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT This Agreement is made and entered into as of the 22nd day of November 1996 (the "Effective Date") by and between Genentech, Inc., a corporation organized and existing under the laws of the State of...Development Collaboration and License Agreement • March 31st, 1997 • Cytotherapeutics Inc/De • Biological products, (no disgnostic substances) • California
1 EXHIBIT 10.62 DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT This Agreement is made and entered into as of the 22nd day of November 1996 (the "Effective Date") by and between Genentech, Inc., a corporation organized and existing under the laws of...Development Collaboration and License Agreement • January 27th, 1998 • Cytotherapeutics Inc/De • Biological products, (no disgnostic substances) • California
Re: Termination of the Development Collaboration and License AgreementDevelopment Collaboration and License Agreement • March 7th, 2024 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
NESTEC and DBV entered into the Agreement to establish a collaboration whereby DBV would develop a diagnostic test for CMPA using DBV’s proprietary Viaskin™ Technology, and NESTEC would receive a license to commercialize such diagnostic product. Through no fault of either party, and after both parties having used Commercially Reasonable Efforts to pursue the development and commercialization of a diagnostic test for CMPA, the parties desire to cease all activities under the Agreement, including, without limitation, all Development activities, and the parties desire to terminate the Agreement in its entirety in accordance with the terms of this letter (this “Letter”), effective as of the last date of signature hereof, (the “Effective Date”).
February 11, 1999 Genentech, Inc. Attn: Mr. Roy C. Hardiman One DNA Way South San Francisco, CA 94080-4990 Re: Development Collaboration and License Agreement between Genentech, Inc. ("Genentech") and Alteon, Inc. ("Alteon"), and Stock Purchase...Development Collaboration and License Agreement • February 19th, 1999 • Alteon Inc /De • Pharmaceutical preparations
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT By and Between DBV TECHNOLOGIES and NESTEC S.A.Development Collaboration and License Agreement • March 22nd, 2017 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
This DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT (together with the exhibits hereto, this “Agreement”) is entered into on this 27th day of May, 2016 (the “Effective Date”), by and between NESTEC S.A., with a place of business at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NESTEC”) and DBV TECHNOLOGIES, S.A., with a place of business at 177-181 avenue Pierre Brossolette 92120 Montrouge France (“DBV”). NESTEC and DBV may each be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NUMBER ONE TO DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDevelopment Collaboration and License Agreement • May 3rd, 2016 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus
This Amendment Number One to Development Collaboration and License Agreement (this “Amendment”) is entered into effective as of January 18, 2016 (the “Amendment Effective Date”) by and among Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc., a Delaware corporation having a principal place of business at 5964 La Place Court, Carlsbad, CA 92008 (“GenMark”), Advanced Liquid Logic, Inc., a Delaware corporation having its principal place of business at 5200 Illumina Way, San Diego, CA 92122 (“ALL”), and Illumina, Inc., a Delaware corporation having a principal place of business at 5200 Illumina Way, San Diego, CA 92122 (“Illumina”). GenMark, ALL and Illumina are hereinafter and in the Agreement (as defined below) referred to individually as a “Party” and collectively as the “Parties” (subject to the qualification below relating to Illumina). Capitalized terms used but not defined herein shall have the meaning given to such terms in the Agreement.
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDevelopment Collaboration and License Agreement • March 22nd, 2013 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California
The Corporation renounces any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of any holder of Series D Preferred that is a strategic operating company, or any director, stockholder, employee or agent of such entity.
DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT Dated September 13th, 2016 by and between JUPITER ORPHAN THERAPEUTICS, INC, a corporation incorporated under the laws of Delaware , having its principal place of business at 601 Heritage Drive...Development, Collaboration and License Agreement • November 9th, 2021 • Jupiter Neurosciences, Inc. • Pharmaceutical preparations
This Development, Collaboration and License Agreement (“Agreement”), dated September 13th, 2016 (the “Effective Date”) is made by and between Jupiter Orphan Therapeutics, Inc. (“JOT”), a corporation organized under the laws of Delaware, United States of America and Aquanova AG a company organized under the laws of Germany (“Aquanova”) (each a “Party” and collectively, the “Parties”).
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDevelopment Collaboration and License Agreement • November 8th, 2012 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California
This Development Collaboration and License Agreement (“Agreement”) is made and entered into as of the 26th day of July, 2012 (the “Effective Date”) by and between Advanced Liquid Logic, Inc., a Delaware corporation having its principal office at 615 Davis Drive, Suite 800, Morrisville NC, 27560 (“ALL”), and Clinical Micro Sensors, Inc., d/b/a Genmark Diagnostics, Inc., a Delaware corporation having its principal office at 5964 La Place Court, Carlsbad, CA 92008 (“GenMark”). ALL and GenMark may each be referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT This Agreement is effective December 18, 1997 ("the EFFECTIVE DATE") by and between Genentech, Inc. ("GNE"), a Delaware corporation located at 1 DNA Way, South San Francisco, CA...Development Collaboration and License Agreement • January 26th, 1998 • Leukosite Inc • Pharmaceutical preparations • Delaware
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT BETWEENDevelopment Collaboration and License Agreement • December 10th, 1997 • Alteon Inc /De • Pharmaceutical preparations • California
AMENDMENT TO THE DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDevelopment Collaboration and License Agreement • April 1st, 2019 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
This AMENDMENT (the “Amendment”) entered into on 12 July 2018 (the “Effective Date”) is an amendment to the DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT dated 27th day of May, 2016, by and between NESTEC S.A., with a place of business at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NESTEC”) and DBV TECHNOLOGIES, S.A., with a place of business at 177-181 avenue Pierre Brossolette 92120 Montrouge France (“DBV”) (the “Agreement”). NESTEC and DBV may each be referred to herein individually as a “Party” and collectively as the “Parties.”
